RxDoctor Payments Data

Christopher Kleeman, MD

Gastroenterology · South Portland, MENPI 1861690471

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Boston Scientific at 47.6% of the total. That places this record below the midpoint for gastroenterology clinicians in ME, where the typical reported total is $670.

$320in general payments, 2019–2025

Across 9 payments — averaging $35.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$152
  • Stryker$40
  • Johnson & Johnson$28
  • AbbVie$24
  • E.r. Squibb & Sons, L.L.C.$21
  • Takeda Pharmaceuticals U.S.A., Inc.$20
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$320100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$320 in reported general payments places this provider in the 30th percentile of 68 gastroenterology providers in Maine.

See all gastroenterology providers in Maine

Medicare billing

Part B allowed, 2024
$55,191
Medicare patients
262
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib11$124,757
Humira(Cf) PenAdalimumab12$79,681
LinzessLinaclotide44$35,652
Mesalamine47$23,264
CreonLipase/Protease/Amylase16$11,760
Mesalamine ErMesalamine18$3,386
Pantoprazole Sodium59$2,130
Budesonide DrBudesonide27$2,061
Budesonide EcBudesonide20$1,507
Dexlansoprazole DrDexlansoprazole12$1,466
Colestipol Hcl28$1,293
Omeprazole61$512
Famotidine35$502
Dicyclomine Hcl32$474
Spironolactone22$360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess, Creon$24$172,16971 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 68 gastroenterology providers in Maine.

Other gastroenterology in South Portland

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →